Hit early, hit hard! Integrated case-based management of CKD in T2DM

Learning objectives

You will learn:

• Benefits of early recognition of kidney disease in type 2 diabetes (T2DM) for improving cardiovascular outcomes
• Reasons why albuminuria is both an important biomarker and a treatment target in patients with T2DM
• Multifactorial drivers of chronic kidney disease (CKD) progression in T2DM and their implications for medical management
• Clinical evidence regarding finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, and international guideline recommendations on its use for the treatment of CKD and T2DM.